ABBV-RGX-314
Wet Age-related Macular Degeneration (AMD)
Key Facts
About REGENXBIO
REGENXBIO is a clinical-stage biotech with a mission to deliver life-changing gene therapies through its foundational NAV Technology Platform. Its achievements include enabling the blockbuster therapy ZOLGENSMA® and building a diverse internal pipeline, most notably in MPS II and Duchenne muscular dystrophy. The company's strategy combines internal development of wholly-owned assets with a high-margin, capital-efficient licensing model that provides recurring revenue and validates its technology.
View full company profileAbout REGENXBIO
REGENXBIO is a clinical-stage biotech with a mission to deliver life-changing gene therapies through its foundational NAV Technology Platform. Its achievements include enabling the blockbuster therapy ZOLGENSMA® and building a diverse internal pipeline, most notably in MPS II and Duchenne muscular dystrophy. The company's strategy combines internal development of wholly-owned assets with a high-margin, capital-efficient licensing model that provides recurring revenue and validates its technology.
View full company profileTherapeutic Areas
Other Wet Age-related Macular Degeneration (AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLS-AX (axitinib injectable suspension) | Clearside Biomedical | Phase 3 Ready |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 2b/3 |
| RGX-314 | REGENXBIO | Phase II |